2024
The effect of plerixafor on autologous stem cell mobilization, cell viability, and apheresis challenges
Puzo C, Li P, Tormey C, Siddon A. The effect of plerixafor on autologous stem cell mobilization, cell viability, and apheresis challenges. Lab Medicine 2024, lmae080. PMID: 39303673, DOI: 10.1093/labmed/lmae080.Peer-Reviewed Original ResearchAutologous stem cell transplantationHematopoietic stem cellsMultiple myelomaG-CSFMobilization failureDiffuse large B-cell lymphomaAutologous stem cell mobilizationLarge B-cell lymphomaGranulocyte colony-stimulating factorAutologous stem cell transplant patientsEfficacy of plerixaforStem cell mobilizationB-cell lymphomaStem cell transplantationEffects of plerixaforRetrospective chart reviewColony-stimulating factorYale-New Haven HospitalCell viabilityMultiple risk factorsHodgkin lymphomaNon-HodgkinMobilization regimenCell transplantationPlerixaforMixed-field ABO front typing as an early sign of disease recurrence in ABO-matched stem cell transplantation
Yurtsever N, Lee E, Pinatti L, Shah B, Tormey C, Siddon A. Mixed-field ABO front typing as an early sign of disease recurrence in ABO-matched stem cell transplantation. Immunohematology 2024, 40: 89-92. PMID: 39373301, DOI: 10.2478/immunohematology-2024-013.Peer-Reviewed Original ResearchConceptsStem cell transplantationCell transplantationDisease recurrenceMyeloid neoplasmsChimerism testingAllogeneic stem cell transplantationSigns of disease recurrenceIndicator of disease recurrenceDonor-recipient pairsABO antigen expressionGraft statusAntigen expressionFemale patientsPost-transplantationAllograft statusTransplantationABO typeRecurrenceClinical settingEarly signsNeoplasmsChimerismEarly indicatorABOEngraftment
2023
Optimizing Donor Chimerism Threshold for Next-Generation Sequencing Monitoring of Measurable Residual Disease Post-Allogeneic Stem Cell Transplantation for Myeloid Neoplasms
Puzo C, Tormey C, Rinder H, Siddon A. Optimizing Donor Chimerism Threshold for Next-Generation Sequencing Monitoring of Measurable Residual Disease Post-Allogeneic Stem Cell Transplantation for Myeloid Neoplasms. Transplantation And Cellular Therapy 2023, 29: 459.e1-459.e4. PMID: 37062510, DOI: 10.1016/j.jtct.2023.04.005.Peer-Reviewed Original ResearchConceptsAllogeneic stem cell transplantationStem cell transplantationDonor chimerismCell transplantationNGS testingPost allogeneic stem cell transplantationMeasurable residual diseaseNext-generation sequencingAcute myeloid leukemiaConditioning regimenRelated donorsMyelodysplastic syndromeResidual diseaseValidation cohortMyeloid leukemiaMyeloid neoplasmsNGS panelLogistic regressionPatientsChimerismSignificant predictorsCharacteristic curveTransplantationRegimenConservative threshold
2018
Be careful of the masquerades: differentiating secondary myelodysplasia from myelodysplastic syndromes in clinical practice
Shallis RM, Xu ML, Podoltsev NA, Curtis SA, Considine BT, Khanna SR, Siddon AJ, Zeidan AM. Be careful of the masquerades: differentiating secondary myelodysplasia from myelodysplastic syndromes in clinical practice. Annals Of Hematology 2018, 97: 2333-2343. PMID: 30109425, DOI: 10.1007/s00277-018-3474-7.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsMyelodysplastic syndromeSecondary myelodysplasiaSecondary causesAllogeneic hematopoietic cell transplantationDiagnosis of MDSRepresentative case seriesUnderlying myelodysplastic syndromeHematopoietic cell transplantationLack of efficacyHematologists/oncologistsMeticulous exclusionResultant cytopeniasIntensive chemotherapyCase seriesMorphologic reviewCell transplantationDiagnostic dilemmaSuch therapyMalignant processExpert hematopathologistsClinical practiceMyelodysplasiaCytogenetic abnormalitiesPatientsSpecialized physicians